Establishment and application of a reverse dot blot assay for 13 mutations of hearing-loss genes in primary hospitals in China
Article Category: Original Article
Publicado en línea: 20 mar 2024
Páginas: 11 - 17
DOI: https://doi.org/10.2478/abm-2024-0003
Palabras clave
© 2024 Qing-Qing Jiang et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Hearing loss is a highly prevalent congenital disease that severely affects the quality of patients' daily life. It is estimated that about 466 million people (5.5% of the population) have disabling hearing loss worldwide (
In the Chinese population, nearly 50% of cases of NSHL are associated with mutations in the following genes:
In China, the traditional audiological examination is applied in most medical institutions for screening deafness at present. However, this traditional examination is not suitable for detecting hereditary deafness [1, 18]. In recent years, more different methods are developed to detect mutations in NAHL-related genes, including classic polymerase chain reaction-restriction enzyme analysis (PCR-RFLP) [19], matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF-MS) [20], gene sequencing, etc. However, due to the limitation of funds and equipment, it is impossible to carry out expensive genetic tests for hearing loss in primary hospitals in China. Therefore, it is necessary to develop an economical and convenient genetic testing method for early detection of hearing loss in primary hospitals.
In this study, we established a reliable gene-detection method based on a reverse dot blot assay combined with a flow-through hybridization technology platform that allows the simultaneous detection and genotyping of 13 hotspot mutations of 4 prominent hearing loss–related genes (
A total of 213 volunteers were collected from Changning Maternity and Infant Health Hospital. This study was approved by the ethics committee of Changning Maternity and Infant Health Hospital (CNFBLLJD-2021-01). Each participant has signed the informed consent. Human whole blood samples were obtained, and genomic DNA was extracted using Hybribio Genomic DNA Extraction Kit (Hybribio) according to the manufacturer's instructions. DNA concentration was measured by NanoDrop 2000 (Thermo Fisher Scientific). In addition, Chaozhou Hybribio Limited Corporation also provided 26 samples of different hearing loss gene mutations verified by gene sequencing. Among them, 13 samples were used for method reproducibility, and the other 13 were used for validation tests.
The hearing loss–detection kit which was designed and made by Chaozhou Hybribio Limited Corporation included a PCR system as follows: one set of primers of
Figure 1.
Schematic representation and results of hearing loss gene chip.
The information on primers in the reaction system
| GJB2-F | (Biotin)-TAGTGATTCCTGTGTTGTGTG |
| GJB2-R | TTCTGGGTTTTTGATCTCCTC |
| GJB3-F | (Biotin)-CTCTTCCTCTACCTGCTGC |
| GJB3-R | TATTGCCTGGGTCTGGAT |
| SLC26A4-F1 | (Biotin)-TTCACTGCTGGATTGCTCA |
| SLC26A4-R1 | GTGTTAACCGTACATGTTCTGC |
| SLC26A4-F2 | (Biotin)-CTCTCAGATGGTATGGCGTC |
| SLC26A4-R2 | TCCTTCATTACTGATTCCTTGTC |
| SLC26A4-F3 | (Biotin)-GTTCTTTGACGACAACATTAG |
| SLC26A3-R3 | AATGGAACCTTGACCCTCTT |
| mtDNA-F1 | (Biotin)-ATGAGGTGGCAAGAAATG |
| mtDNA-R1 | TTGGCTAAGGTTGTCTGGTA |
| mtDNA-F2 | (Biotin)-GATGCATACACCACATGAAAC |
| mtDNA-R2 | TGAGTGTTAGGAAAAGGGCA |
| mtDNA-F3 | (Biotin)-CACAATGGGGCTCACTCA |
| mtDNA-R3 | ACGAACAATGCTACAGGGAT |
The information of probes in the hearing loss gene chip
| 1494-PN | CGTCACCCTCCTCAAG |
| 1494-PM | CCGTCACTCTCCTCAAG |
| 1555 PN | AGAGGAGACAAGTCGTAAC |
| 1555 PM | GAGGAGGCAAGTCGTAA |
| 7445 PN | ACATAAAATCTAGA-CAAAAAAGGA |
| 7445 PM | CATAAAATCTAGGCAAAAAAGG |
| 12201 PN | GACCCCTTATTTACCGAGAA |
| 12201 PM | CCCCTTACTTACCGAGA |
| G2-35 PN | GTTCACACCCCCCAGGA |
| G2-35 PM | AATGGAACCTTGACCCTCTT |
| G2-155 PN | GGTGTTGCAGACAAAGTCG |
| G2-155 PM | CGACTTTGCAACACCC |
| G2-176 PN | GCACACGTTCTTGCAGCC |
| G2-176 PM | CAGCCAGCTACGATCAC |
| G2-235 PN | AGCTGCAGGGCCCATA |
| G2-235 PM | TATGGGCCTGCAGCT |
| G2-299 PN | TTCTTCTCATGTCTCCGGT |
| G2-299 PM | ACCGGAGACGAGAAGAA |
| G3-538 PN | ACATTGCCCGACCTAC |
| G3-538 PM | ACATTGCCTGACCTACC |
| IVS7-2 PN | GTTTTATTTCAGACGATAATTGC |
| IVS7-2 PM | TGTTTTATTTCGGACGATAAT |
| 1229 PN | CTGCTCTTTCCCGCACGG |
| 1229 PM | CTCTTTCCCGCATGGCC |
| 2168 PN | CGGTCCATGATGCTATA |
| 2168 PM | GTCCGTGATGCTATACT |
The PCR amplification was carried out in strict accordance with the manufacturer's procedure [21]. Briefly, the PCR amplification system contained a total reaction volume of 30 μl containing 50 ng of DNA template, 28 μl 2 × GC buffer, 4 mmol/L MgCl2, 0.2 mmol/L of each primer (
Hybridization reactions were carried out using HMM2I (Chaozhou Hybribio Limited Corporation) as in our previous study [22]. The details of the flow-through hybridization method are as follows: first, directly incubate the PCR products (target molecules) with the membrane fibers that contain the immobilized probes. Then, the complementary molecules are retained on the membrane by the formation of duplexes with a probe. After a careful wash, the streptavidin–horseradish peroxidase conjugate binds to biotinylated PCR products, and a certain substrate (nitro-blue tetrazolium-5-bromo-4-chloro-3-indolylphosphate, BCIP) is added to detect the hybrids. The results were interpreted by direct visualization [22].
In each assay, three kinds of quality controls were used, including blank control, negative control, and positive control. The blank control was ddH2O, the negative control was provided by Chaozhou Hybribio Limited Corporation, and the positive control was purchased from Guangzhou BDS Biological Technology Co., Ltd.
Two different batches of reagents and instruments from different manufacturers (GeneAmp7500 of PE Applied Biosystems and MJ Mini Personal Thermal Cycler of Bio-RAD Company) were used to analyze 13 samples with different genotypes of hearing loss to validate the reproducibility and precision of this assay. Each sample detection was performed five times. Statistical analysis was carried out for each sample.
The PCR amplification products of 13 mutations in 4 hearing loss–related genes, including
All data were analyzed by SPSS version 17.0 statistical software (SPSS Inc.). The crude percent agreement between the reverse dot blot assay and the DNA sequencing was the percentage of samples with identical results by both methods. Absolute agreement and Cohen's kappa statistics were applied to assess the consistency of the results of the two detection methods.
The visual results of the hybridization reactions of the hearing-loss genes are shown in
Thirteen samples with different mutation sites of hearing-loss genes were detected at least five times in order to evaluate the reproducibility of the reverse dot blot assay. All the wild-type and mutant dot blots exhibited the same depth of color each time. There were no differences among them.
In a verification test, we chose another 13 samples with different genotypes of mutation sites of hearing-loss genes. All these genomic DNA samples were detected by both DNA sequencing and our reverse dot blot assay, and the results were consistent with each other. Moreover, the reverse dot blot assays were performed by two operators with different batches of reagents and two different PCR instruments (GeneAmp7500 and MJ Mini Personal Thermal Cycler), and the results were then also consistent.
After establishing the hearing loss gene mutation detection system, we applied the detection system in a primary hospital. A total of 213 genomic DNA samples were collected and performed the hearing loss gene mutation analysis. Of the 213 volunteers, a total of 9 participants carried hearing loss gene mutate alleles, which indicates a positive rate of 4.23% (
Figure 2.
Detection of deafness gene mutations in 213 volunteers.
The genotypes of nine individuals with hearing loss gene mutation
| c.35delG | 0 | c.538C>T | 0 | IVS7-2A>G | 2 | m.1494C>T | 0 |
| c.155_158del4 | 0 | c.1229C>T | 1 | m.1555A>G | 1 | ||
| c.176_191del16 | 0 | c.2168A>G | 0 | m.7445A>G | 0 | ||
| c.235delC | 4 | m.12201T>C | 0 | ||||
| c.299_300delAT | 1 |
More than 50% of hearing-loss cases have genetic causes. The 2014 American College of Medical Genetics and Genomics (ACMG) guidelines have underlined the importance of an etiological diagnosis for hearing loss, in which genetic testing is recommended to be included in the workup of patients with NSHL [24]. In China, it is very important to establish a convenient, economical, rapid, and effective genetic-detection method for NSHL diagnosis in primary hospitals.
Here, we established a new gene-detection system by using a reverse dot blot assay technique. It could simultaneously detect 13 hot mutations of hearing loss–related genes, enabling effective analysis of the genetic information in a sample. The key feature of this system is the use of the common PCR instrument to amplify hearing loss–related genes followed by a specific reverse dot blot assay with site-specific probes to identify the 13 mutation sites. Each mutation site was detected by a specific probe. The reverse dot blot assay system ensures that all the 13 mutation sites can be identified in a single reverse dot blot membrane.
According to the reported studies, various methods were used to detect hearing-loss genes, such as probe melting curve [25], microarray [26], amplification refractory mutation system PCR [27], denaturing gradient gel electrophoresis (DGGE) [28, 29], and denaturing high-performance liquid chromatography (DHPLC) [30]. However, these methods have the disadvantages of being expensive or not being accurate enough. At present, genetic screening for hearing loss is not widely available in primary hospitals in China. Although quantitative PCR is used in some institutions or hospitals to detect mutations of hearing loss–related genes, the equipment is expensive and cannot be widely used in primary hospitals. Our detection method does not require special equipment. In general, our reverse dot blot assay has the following advantages: first, compared with other methods that can detect only 9 mutation sites, this method can detect 13 common mutation sites of 4 hearing loss–related genes simultaneously. It is necessary to increase the screening of deafness gene mutation sites in primary hospitals. Second, a gene-detection system can be easily performed, as the PCR amplification can be set up in all instruments. It will also possible to establish automatic detection in the future. Third, the flow through the hybridization platform can effectively shorten the hybridization time by about 4.5 h, from 6 h to 1.5 h [22]. The reverse dot blot assay could process 16 samples and get the detection result within 1.5 h in a single run. The sample size of each run of our detection system is larger than that of other methods, leading to time-saving. However, the reverse dot blot assay also has some disadvantages: while 13 mutations can be detected by this method, other known–unknown mutations have not yet been detected. In the future, we can easily add more detection sites to our detection system.
In fact, we applied the gene-detection system in a primary hospital in Shanghai, China. The results of hearing loss gene mutation analysis with 213 genomic DNA samples indicated a positive rate of 4.23%. The mutation distribution of deafness genes in these samples was consistent with those in the Chinese population. The results indicate that this method is feasible to be applied in Chinese primary hospitals. Nevertheless, this study has some limitations. First, this detection method is only used to detect 13 mutation sites in 4 common hearing-loss genes in the Chinese population, and it does not cover all mutation sites related to hearing-loss genes. Therefore, even if the test result is negative, it cannot be ruled out that the subject has other mutation sites related to hearing-loss genes. Second, test results can only assist in making a clinical diagnosis. Clinicians must make a diagnosis of patients in combination with other clinical examinations, medical history, etc. Moreover, in the present study, the sample size is relatively small, with only more than 200 cases. Therefore, in follow-up studies, we will expand the sample size to further explore the distribution of deafness gene mutation sites in the Chinese population. Despite this, this method still has great clinical application prospects. It can not only be used as a screening method for high-risk populations, but can also be widely used in primary hospitals.
In conclusion, we have established a novel gene-detection system based on the reverse dot blotting assay technique to simultaneously detect 13 mutation sites in 4 hearing loss–related genes. The reverse dot blot assay ensures their liability and visualization of this gene-detection system. The detection system is widely applicable to common PCR instruments, and it is easy to manipulate and is of low cost, high performance, and high accuracy. It has a wide clinical application prospect.